Tags

Type your tag names separated by a space and hit enter

Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.
Immunotherapy. 2020 Oct; 12(15):1127-1132.I

Abstract

Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivation of the immune system, better known as cytokine storm syndrome. Tocilizumab has been proposed to treat COVID-19 severe cases associated to ARDS. Results & methodology: Here we present two successful cases of tocilizumab administration in two COVID-19 patients with prior administration of antiviral therapy (hydroxychloroquine, azithromycin, lopinavir and ritonavir) with adequate response and resolution of ARDS, septic shock and severe pneumonia within the first 72 h. Discussion & conclusion: This case supports the usage of tocilizumab as an effective therapy in COVID-19 associated cytokine storm syndrome. Further studies should be done in order to assess its effectiveness and security.

Authors+Show Affiliations

Infectious diseases, Clínica de Marly, Bogotá 110231, Colombia.Infectious diseases, Clínica de Marly, Bogotá 110231, Colombia.Infectious diseases, Clínica de Marly, Bogotá 110231, Colombia.Asociación Colombiana de Infectología, Bogotá 110111, Colombia.Infectious diseases, Clínica de Marly, Bogotá 110231, Colombia. Infectious diseases, Hospital La Samaritana, Bogotá 110321, Colombia.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

32664810

Citation

Cala-García, Juan David, et al. "Recovery of COVID-19 Acute Respiratory Distress Syndrome With Tocilizumab: Successful Outcome in Two Critically Ill Patients." Immunotherapy, vol. 12, no. 15, 2020, pp. 1127-1132.
Cala-García JD, Sierra-Bretón JD, Cavelier-Baiz JE, et al. Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients. Immunotherapy. 2020;12(15):1127-1132.
Cala-García, J. D., Sierra-Bretón, J. D., Cavelier-Baiz, J. E., Faccini-Martínez, Á. A., & Pérez-Díaz, C. E. (2020). Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients. Immunotherapy, 12(15), 1127-1132. https://doi.org/10.2217/imt-2020-0154
Cala-García JD, et al. Recovery of COVID-19 Acute Respiratory Distress Syndrome With Tocilizumab: Successful Outcome in Two Critically Ill Patients. Immunotherapy. 2020;12(15):1127-1132. PubMed PMID: 32664810.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients. AU - Cala-García,Juan David, AU - Sierra-Bretón,Juan David, AU - Cavelier-Baiz,Jorge Eduardo, AU - Faccini-Martínez,Álvaro A, AU - Pérez-Díaz,Carlos Eduardo, Y1 - 2020/07/14/ PY - 2020/7/16/pubmed PY - 2020/10/21/medline PY - 2020/7/16/entrez KW - ARDS KW - C-reactive protein KW - COVID-19 KW - IL-6 KW - SARS-CoV-2 KW - cytokine storm syndrome KW - hyperinflammation KW - immunotherapy KW - monoclonal antibodies KW - severe pneumonia KW - tocilizumab SP - 1127 EP - 1132 JF - Immunotherapy JO - Immunotherapy VL - 12 IS - 15 N2 - Background: Severe pneumonia and acute respiratory distress syndrome (ARDS) due to COVID-19 is a challenge for nowadays medical practice. Although there is no clarity in the principal mechanism of lung damage and ARDS development, it has been suggested that one of the main reasons of this pathology is the hyperactivation of the immune system, better known as cytokine storm syndrome. Tocilizumab has been proposed to treat COVID-19 severe cases associated to ARDS. Results & methodology: Here we present two successful cases of tocilizumab administration in two COVID-19 patients with prior administration of antiviral therapy (hydroxychloroquine, azithromycin, lopinavir and ritonavir) with adequate response and resolution of ARDS, septic shock and severe pneumonia within the first 72 h. Discussion & conclusion: This case supports the usage of tocilizumab as an effective therapy in COVID-19 associated cytokine storm syndrome. Further studies should be done in order to assess its effectiveness and security. SN - 1750-7448 UR - https://www.unboundmedicine.com/medline/citation/32664810/Recovery_of_COVID_19_acute_respiratory_distress_syndrome_with_tocilizumab:_successful_outcome_in_two_critically_ill_patients_ DB - PRIME DP - Unbound Medicine ER -